Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial

Pharmacology, Toxicology and Pharmaceutical Science

• Remdesivir 100%
• Placebo 100%
• Beta1a Interferon 100%
• Adverse Event 22%
• Oxygen 22%
• Infection 9%
• Maintenance Dose 4%
• Mortality 4%
• Blindness 4%
• Symptom 4%
• Functional Disease 4%
• Antivirus Agent 4%
• SARS Coronavirus 4%
• Disease Severity 4%
• Aspartate Aminotransferase 4%
• Alanine Aminotransferase 4%
• Pathogenesis 4%
• Allergy 4%
• Pneumonia 4%
• Interferon 4%
• Lower Respiratory Tract Infection 4%